DAWSON JAMES SECURITIES


Jan 03, 08

NEW STORY
08:00 ET Dawson James Securities Initiates Research Coverage on NovaBay Pharmaceuticals (Amex: NBY) With a Speculative Buy Rating -- 12-18 Month Target Price $8.00

 
Aug 29, 07

08:00 ET Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price

 
Jul 12, 07

07:30 ET Dawson James Securities Initiates Research Coverage on A.P. Pharma, Inc. (Nasdaq: APPA) with a Speculative Buy Rating - 12-18 Month Target Price $4.50

 
May 22, 07

12:30 ET Dawson James Securities Reiterates Speculative Buy Recommendation on Biopure Corp. (Nasdaq: BPUR) with $3.00 Price Target.

 
May 11, 07

13:25 ET Dawson James Securities Reiterates Speculative Buy Recommendation on iCAD, Inc. (Nasdaq: ICAD) with $5.00 Price Target

 
May 02, 07

11:06 ET Dawson James Securities Initiates Research Coverage on TranSwitch Corp. (Nasdaq: TXCC) with a Speculative Buy Rating - 12-18 Month Target Price $2.50

 
Apr 02, 07

13:09 ET Dawson James Securities Reiterates Strong Buy Recommendation on Antares Pharma (Amex: AIS) with $4.00 Price Target

 
Jan 30, 07

08:30 ET Dawson James Securities Initiates Research Coverage on Neurobiological Technologies, Inc. (Nasdaq: NTII) with a Speculative Buy Rating -- 12-18 Month Target Price $7.00

 
Jan 04, 07

17:03 ET Dawson James Securities Discusses 2007 Outlook for Biopure and Viragen

 
Mar 16, 06

08:00 ET Dawson James Securities Upgrades Antares Pharma to Strong Buy With $4.00 Price Target

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2008 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.